Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ: ANIP) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 25.9% year on year to $266 million. On the other hand, the company’s full-year revenue guidance of $1.11 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $2.21 per share was 8.2% above analysts’ consensus estimates.

Is now the time to buy ANIP? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

ANI Pharmaceuticals’ second quarter was marked by strong year-on-year growth in its rare disease and generics businesses, but the market reacted negatively to the results. Management highlighted the rapid scale-up of its sales force for Cortrophin Gel and robust demand across existing specialties. CEO Nikhil Lalwani noted, “We are seeing significant momentum in demand in the third quarter with July representing the highest month for new cases initiated,” attributing quarterly performance to persistent execution and expansion efforts.

Looking forward, ANI Pharmaceuticals’ guidance is shaped by the anticipated ramp of its expanded rare disease sales force and the continued penetration of Cortrophin Gel into new specialty areas, particularly gout. Management expects the business to benefit from the full deployment of its newly trained team and strong demand drivers, with Lalwani stating, “We believe we are well-positioned to achieve our revised 2026 guidance based on the continued momentum in existing specialties and the strong demand generation from the gout expansion.” The company also emphasized its confidence in operating leverage from these investments carrying into next year.

Key Insights from Management’s Remarks

Management attributed quarterly growth to sustained momentum in rare disease therapies, the successful scale-up of its sales force, and new product contributions, while also acknowledging a recalibration of guidance to reflect first-half results.

• Cortrophin Gel expansion: The company’s largest-ever sales force expansion, increasing headcount by 50% to 180 representatives, was completed by the end of June. This expansion targets both primary care and podiatry settings for acute gouty arthritis flares, aiming to capture underpenetrated patient populations previously managed outside specialty care.
• Strong demand indicators: Management noted that over 95% of new sales representatives generated multiple new Cortrophin cases, and more than a third of prescribers initiated two or more cases each. These leading indicators suggest broad and deep uptake, with July setting a record for new cases initiated.
• Ophthalmology and specialty traction: Cortrophin’s base business in specialties like nephrology, neurology, ophthalmology, pulmonology, and rheumatology continues to grow. Notably, ophthalmology volumes doubled year-over-year, reflecting deeper penetration in key therapeutic areas.
• Generics business resilience: The company launched 12 new generics so far this year and remains on track for at least 15 launches in 2026. ANI’s U.S.-based manufacturing footprint is positioned to benefit from tariff changes affecting the broader pharmaceutical supply chain.
• Harmony out-licensing contribution: The out-licensing agreement with Harmony Biosciences provided incremental revenue in the quarter, supplementing organic growth and highlighting the company’s willingness to leverage partnerships for additional income streams.

Drivers of Future Performance

Management’s outlook centers on sustained rare disease growth and operating leverage from the expanded sales force, offset by a modest recalibration of full-year revenue expectations.

• Gout expansion momentum: The full impact of the sales force expansion in gout is expected to materialize in the second half of the year, with management citing “very strong demand generation” and record new patient case volumes. The company believes the underpenetrated acute gouty arthritis segment can drive a step-change in revenues as more primary care and podiatry prescribers adopt Cortrophin.
• Existing specialties growth: Continued momentum in high-value specialties such as nephrology and ophthalmology is projected to support multi-year growth. Management emphasized that existing specialties remain “significantly underpenetrated,” providing a long runway for patient adoption and revenue expansion.
• Operational leverage and discipline: The company expects to achieve operating leverage in 2027, with investments made in 2026—particularly in sales force expansion—supporting higher sales and margin improvement next year. Management also noted a disciplined approach to capital allocation, with a focus on potential M&A to further expand the rare disease portfolio.

Catalysts in Upcoming Quarters

In the coming quarters, our team will be closely monitoring (1) the pace of Cortrophin Gel uptake in primary care and podiatry following the sales force expansion, (2) sustained growth in established specialty areas such as ophthalmology and nephrology, and (3) execution against the target for new generics launches. Additional attention will be paid to early signs of operating leverage and updates on M&A activity in rare diseases.

ANI Pharmaceuticals currently trades at $77.42, down from $82.63 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.